New England Journal of Medicine· 2017Q1

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

Johannes Oldenburg, Johnny Mahlangu, Benjamin Kim, Christophe Schmitt et al.

1,090citations
Q1SCImago
2017year

Short summary

Once-weekly subcutaneous emicizumab prophylaxis reduced annualized bleeding rates by 87% (2.9 vs. 23.3 events) in patients with hemophilia A and inhibitors compared to no prophylaxis.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Hematology

HematologyMedicine